Catalog No.: PC-47108Not For Human Use, Lab Use Only.
GZ-793A is a potent, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) with Ki of 30 nM, inhibits methamphetamine-evoked endogenous dopamine release with IC50 of 10.6 uM.
GZ-793A is a potent, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) with Ki of 30 nM, inhibits methamphetamine-evoked endogenous dopamine release with IC50 of 10.6 uM.
GZ-793A (15 mg/kg, s.c.) specifically decreased methamphetamine (METH) self-administration, without the development of tolerance.
GZ-793A did not serve as a substitute for self-administered METH.
GZ-793A blocked METH-induced conditioned place preference (CPP) and did not induce CPP alone.
